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Dexamethasone inhibited human immunodeficiency virus type 1 (HIV-1) long terminal repeat (LTR)-directed gene expres-
sion in cells of T and B lymphoblastoid lineages, but not in monocytic cells. Suppression required an intact glucocorticoid
receptor (GR), as it was amplified by transfection of lymphocytes with a plasmid encoding the human GR and blocked by
the receptor antagonist RU486. These results were in direct contrast to the effects of dexamethasone on a murine leukemia
retrovirus promoter where, consistent with the findings of others, activation of gene expression was obtained. Potential
regions of the HIV-1 LTR mediating these effects were sought, with sequence homologies predicting two new glucocorticoid
response element half-sites, GRE-II (nucleotides 06 to 01) and GRE-III (/15 to /20), downstream from a previously
identified GR DNA binding domain, GRE-I (0264 to 0259). Mutational analyses documented the loss of inhibitory activity
attendant on changes in GRE-III and the independence of steroid-mediated effects from GRE-I and GRE-II. Consistent with
these findings, electrophoretic mobility shift assays revealed a difference in binding of cellular factors to GRE-III in cells
of T and B lymphocyte vs. monocytic lineages. Binding sites for the cellular transcription factor leader binding protein (LBP-
1) were found to overlap with GRE-III, and LBP-1 interacted with this element in the HIV LTR only in T and B lymphocytic
extracts. We hypothesize that GRE-III sequence-specific effects, including modulation of LBP-GR interactions, underlie the
negative regulatory effect of glucocorticoids on HIV-1 gene expression, with some specificity for cell type. q 1995 Academic
Press, Inc.
INTRODUCTION clinical significance as various disorders frequently
found in HIV disease are treated with short-term or pro-
Human immunodeficiency virus (HIV) gene expression longed courses of steroids. The potential for regulation of
is governed in large part by its 5* long terminal repeat HIV transcription by steroids has a precedent in several
(LTR), a complex modular structure of protein binding systems. Glucocorticoids, mineralocorticoids, thyroid
sites through which both viral and host specific cellular hormone (T3), and active metabolites of vitamins A (reti-
factors interact. Viral proteins, including the trans-activat- noic acid) and D3 modulate transcription in target cells
ing protein Tat (Cullen, 1991), and cellular factors, posi- by binding of hormones to nuclear receptors belonging
tively regulate HIV expression (Jones et al., 1988). Other to a superfamily of related molecules (Martinez et al.,
cellular molecules, such as leader binding protein (LBP- 1991; Tsai et al., 1988), followed by the interaction of
1), have more complex relationships with the LTR, lead- these complexes with defined DNA sequences, termed
ing to positive (Jones et al., 1991) and negative (Yoon et hormone response elements (Beato, 1991).
al., 1994) effects, depending upon a variety of exogenous Glucocorticoid response elements (GRE) have been
factors. The LTR also includes a functional negative regu- identified in promoters of a variety of mammalian retrovi-
latory element (NRE, nucleotides 0340 to 0185) which ruses (Miksicek et al., 1986; Cordinely et al., 1987), as
binds viral and cellular factors, including glucocorticoid well as in some DNA viruses (Chan et al., 1989; Kupfer
receptor (GR) (Ghosh, 1992). The relationship of such et al., 1990). They consist of a 15 nucleotide consensus
binding to the process of transcriptional suppression of palindrome, GGTACAnnnTGTTCT, with the TGTTCT half
HIV are yet uncertain, however. site as an essential core element (Beato, 1991). Prelimi-
We have been interested in the role of glucocorticoids nary studies from this laboratory (Laurence et al., 1989)
in the modulation of HIV replication (Laurence et al., and others (Miksicek et al., 1986; Kolesnitchenko et al.,
1989; Mitra et al., 1993). Such studies are of potential 1992; Soudeyns et al., 1993) predicted the existence of
a GRE-like sequence within the NRE of the HIV-1 LTR.
An imperfect palindrome is formed with one GRE half1 To whom reprint requests should be addressed.
site, AGAACA, at nucleotides0264 to0259, and another,2 Current address: Dept. of Biology, City University of New York, New
York, NY 10032. GCTTGT, at 0255 to 0250. These sequences, collec-
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tively known as GRE-I, are conserved throughout diverse mg/ml in 70% ethanol and diluted in culture medium to
give final concentrations of 1005 to 10010 M. The GRHIV-1 isolates. Physical interaction of the GR DNA bind-
ing domain with GRE-I has been demonstrated (Ghosh, inhibitor RU486 [17b-hydroxy-11b-(4-dimethyl amino-
phenoyl-17a-(prop-1-ynyl)estra-4,9-diene-3-one] (Mifepri-1992). However, the functional role of GRE-I in the tran-
scriptional activity of the HIV-1 LTR is suspect (Soudeyns stone, Roussel-Uclaf, France), a structural homolog of
DXM, was a gift of Dr. Stoney Simon, National Instituteset al., 1993), and other potential LTR GRE sites have not
been investigated. of Health, Bethesda, MD. It was used as a stock solution
of 2 mM in 70% ethanol, diluted in culture medium to aAdrenal steroids have a positive regulatory effect on
types B (murine mammary tumor virus, MMTV) and C final concentration of 1006M.
(murine leukemia virus, MLV) retroviruses, the LTRs of
Plasmid constructswhich have multiple GRE sites (Miksicek et al., 1986;
Cato et al., 1988). In contrast, we had shown that the
The reporter plasmid pC15CAT (Arya et al., 1985) con-
glucocorticoid dexamethasone (DXM) blocked phorbol
tains sequences for SV40 regulatory genes, bacterial
ester-mediated upregulation of HIV replication and Tat-
chloramphenicol acetyl transferase (CAT), and the HIV-
mediated LTR driven gene expression in cell lines chroni-
1 LTR. Another LTR-CAT construct, pU3R3, a gift of Dr.
cally infected with HIV-1 (Laurence et al., 1989; Mitra et
Craig Rosen, was also used. The tat plasmid pCV-1 con-
al., 1993). Glucocorticoid-mediated inhibition of HIV-1
tains a 1.8-kb fragment of HIV-1 cDNA encompassing
was also seen in human peripheral blood mononuclear
the tat gene (Arya et al., 1985). The plasmid pRSV-GR
cells (Lu et al., 1995). Although the magnitude of reduc-
(Giguere et al., 1986) encodes human GR under the con-
tion of HIV-1 RNA copy number and p24 Gag antigen in
trol of an RSV promoter and was provided by Dr. Ronald
these cells was only two to threefold, only early time
M. Evans of Salk Institute, La Jolla, CA. The plasmid
points (£96 hr postinfection) were examined, and lym-
pRSV-bGal was a gift of Dr. S. K. Goswami of SUNY
phocyte and monocyte subpopulations were not studied
Health Science Center, Brooklyn, NY.
separately.
We have now completed a comprehensive study of Mutant plasmid constructs
the functional effects of glucocorticoid on HIV-1 LTR-
mediated gene expression in uninfected cell lines of T, p142 CAT was prepared by deleting sequences in the
LTR of pC15CAT upstream of nucleotide 0142 (followingB, and monocyte lineages. We found that DXM negatively
regulated HIV-1 LTR driven gene expression, in the pres- the HIV-1 numbering system used by Garcia et al., 1989),
utilizing a HpaII restriction site. The LTR of pC15CAT wasence and absence of Tat, in a cell lineage-specific man-
ner. This effect was steroid specific, as it was dependent isolated by HindIII digestion and treated with HpaII to
create two fragments. The smaller fragment (0142 toupon GR expression and blocked by the GR antagonist
RU486. It was independent of the GRE-I consensus in /80) was repaired at both ends, a HindIII linker was
added, and recloned in the sense orientation with re-the HIV-LTR NRE, but required one of two GRE-like half-
sites adjacent to the start of transcriptional initiation. This spect to CAT. The linker substitution mutant 0273/0256
NXS, replacing 18 bp of wild-type sequence encom-phenomenon appears to involve suppression of binding
of a cellular factor important in transcriptional regula- passing GRE-I with an NdeI–XhoI–Sal I polylinker, and
its wild type construct pXLTRCAT (Zeichner et al., 1991),tion, LBP-1.
were obtained from Dr. James Alwine.
MATERIALS AND METHODS Plasmids containing three base pair changes in critical
Cells DNA–GR contact residues of GRE-I, as well as in a sec-
ond GRE-like consensus in the HIV-1 LTR, which we referImmortalized human CD4/ cell lines of T (Jurkat, SK23),
to as GRE-II (Fig. 1), were constructed using a modifica-B (Raji), and monocytic (U937, THP-1) lineages were ob-
tion of the oligonucleotide-directed gap heteroduplextained from the American Type Culture Collection (Rock-
technique (Nabel, et al., 1987). In brief, a linearized,ville, MD). SK23 is an HIV negative, CD4/ human T cell
BamHI digested fragment of pU3R3 was incubated withhybridoma, prepared by fusion of peripheral CD4/ T cells
a gapped, BglII treated fragment of the same constructfrom an HIV seropositive individual with the CD4/ T cell
in the presence of mutated oligonucleotides. These seg-line KE37 (Sikder et al., 1994). All cells were cultured at
ments were denatured, re-annealed, and repaired bya density of 0.5 1 106/ml in RPMI-1640 containing 10%
DNA pol (Klenow fragment) and DNA ligase before beingfetal bovine serum depleted of steroids by dextran-char-
transforming into Escherichia coli. Mutant colonies werecoal adsorption (Laurence et al., 1989).
identified with kinase-labeled oligonucleotide (Grun-
Reagents stein et al., 1975), and mutations were confirmed by
southern hybridization and dideoxy sequencing (USBDexamethasone (9a-fluoro-16a-methyl-prednisolone)
(Sigma Chemical Co.) was used as a stock solution of 1 Sequenase kit).
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FIG. 1. Documented and potential transcriptional regulatory sequences in the HIV-1 long terminal repeat. The relative positions of the binding
sites for cellular factors AP-1, NFAT-1, USF, NF-kB, SP-1, LBP-1, etc. are illustrated. U, unique 3*; R repeat; NRE, negative regulatory element; TAR,
trans-acting responsive element. The sequences responsible for glucocorticoid receptor binding are highlighted and written in the order 5* to 3*,
GRE-I, -II and -III, respectively.
Constructs containing clustered point mutations (CPM) range of the assay. Incubations were followed by extrac-
tion with ethyl acetate and ascending thin layer chroma-encompassing the second and third GRE-like sites in
the HIV-1 LTR, 05//1CPM (GRE-II), and /15//20CPM tography. Chromatograms were autoradiographed and
areas of radioactivity cut out and counted in scintillation(GRE-III), were provided by Dr. K. Jones of the Salk Insti-
tute, La Jolla, CA (Jones et al., 1988). fluid. All groups were compared statistically by paired
student’s t tests.A map of these three GRE consensus sequences and
their relationship to other binding segments in the HIV-
Electrophoretic mobility shift assays (EMSA)1 LTR is provided in Fig. 1.
Complementary strands of 27 nucleotide oligomers,
Plasmid transfections and CAT assays
representing nucleotides 0274 to 0256 (GRE-I), 018 to
/9 (GRE-II), and /6 to /32 (GRE-III) of the HIV-1 LTRThese experiments were performed as previously de-
scribed (Sikder et al., 1994), with minor modifications. (IIIB isolate), were obtained from Research Genetics, Inc.
(Huntsville, AL). A 100 nucleotide fragment from the HIV-The 107 cells were washed with serum free (sf) RPMI-
1640 and resuspended in 4 ml sfRPMI containing 400 1 LTR (019 to /80) was obtained by using PvuII and
HindIII restriction digestion, eluting out the appropriatemg/ml DEAE-dextran (Sigma) in 50 mM Tris–HCl, pH 7.3,
with 5–10 mg total plasmid DNA per condition and 100 fragment from a polyacrylamide gel. A 27-mer containing
a consensus GRE oligonucleotide, TGTACAGGATGT-mM of chloroquine (Sigma). Cells were incubated at 377
for 1 hr, washed with sfRPMI, resuspended in fresh cul- TCT, was obtained from Promega (Madison, WI).
Nuclear extracts were prepared by a small scale-rapidture medium, and divided into two or three aliquots of
equal cell number. DXM and RU486 were added to se- method (Osborne et al., 1989). In brief, 2 1 107 cells were
lysed in buffer containing 0.1% NP40, 10 mM Hepes, pHlected aliquots after transfection. After incubation for 40 –
45 hr, cells were harvested, washed, and resuspended 7.9, 1.5 mM MgCl2 , 10 mM KCl, and 0.5 mM DTT. The
nuclear pellet was resuspended in a high salt bufferin 100 ml of 0.25 M Tris–HCl, pH 7.8, and cell extracts
were prepared by three cycles of freezing (in dry ice- containing 0.42 M NaCl, 20 mM Hepes, pH 7.9, 1.5 mM
MgCl2 , 0.5 mM DTT, 0.5 mM PMSF, 0.2 mM EDTA, andethanol) and thawing. Extracts were centrifuged and pro-
tein content in supernatants estimated using the micro- 25% glycerol and incubated on ice for 15 min. The mixture
was then centrifuged for 10 min at 12,500 1g, the super-BCA reagent kit (Pierce, Rockford, IL).
b-Gal expression was estimated by the CPRG-b-Gal natant was diluted with 5 vol of storage buffer (20 mM
Hepes, pH 7.9, 0.1 M KCl, 0.5 mM PMSF, 0.5 mM DDT,method (Hollan et al., 1989). In our system, equivalent
results were obtained when CAT activity was normalized 0.2 mM EDTA, and 20% glycerol) and kept in aliquots at
707. The 100 ng of duplex oligo was end-labeled with 50for protein concentration or b-gal activity. The data pre-
sented here are based on CAT activity, determined by mCi of [g32P]ATP (3000 Ci/mmol, NEN) using T4 poly-
nucleotide kinase (NEB). The labeled oligo was recov-incubating aliquots of cell extracts containing equal
amounts of protein (£10 mg) with [14C]chloramphenicol ered with a Sephadex G-50 quick spin column (Phar-
macia). Binding reactions (20 ml) were set up with either(57.9 mCi/mmol, NEN) and 2.5 mM acetyl coenzyme A
(Pharmacia) at 377. Varying incubation times (30 min to 5mg of nuclear extract or 100–200 ng of purified recombi-
nant GR DNA binding domain (obtained from Dr. K. Yama-2 hr) were examined, ensuring that we were in the linear
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TABLE 1 Table 2 depicts several similar experiments document-
ing DXM-mediated suppression at 2 days of culture,Kinetics of the Effect of DXM on tat-Activated, HIV–LTR-driven
ranging in magnitude from 45 to 98%, and its GR specific-CAT Expression in CD4/ T Cells
ity. Equimolar concentrations of the steroid receptor an-
CAT activity tagonist RU486, a structural homolog of DXM, blocked
Experimental Duration of DXM DXM mediated downregulation of CAT. This latter effect
condition exposure (hours) % acetylation % inhibition
is noteworthy, as in many human T and B cell lines a 10-
fold molar excess of RU486 may be required to achieveLTR-CAT — 2.0 —
LTR-CAT / tat — 67.5 — complete inhibition of DXM effects (Denton et al., 1993).
LTR-CAT / tat 5 44.5 34.1
LTR-CAT / tat 20 41.3 38.8
Cell lineage restriction of DXM effectLTR-CAT / tat 30 35.6 47.2
LTR-CAT / tat 45 30.9 54.2
Possible cell type specificity of the inhibition of LTR-
Note. Cotransfections were carried out with 107 SK23 T cells for each directed gene expression by DXM was next investigated.
condition, with cultures exposed to DXM (1006 M) for varying periods. In CD4/ Raji B cells,1% basal CAT activity was consis-
All cultures were harvested at 45 hr. 2.5 mg of cellular protein extract tently noted following transfection with HIV-1 LTR CAT
was used for each assay. These data represent the means of three
plasmids (Table 2). Cotransfection of pCV-1, a tat con-experiments.
taining plasmid, with LTR resulted in a 40- to 60-fold
enhancement in CAT expression. DXM (1006 M) consis-
tently inhibited this expression, albeit the magnitude ofmoto of UCSF and Dr. L. Freedman of Sloan Kettering
Cancer Institute, NY). The 0.1–0.5 ng of labeled oligo suppression was less than in T cells. Cotransfection of
plasmid pRSVGR, containing the gene for human GR,(10,000 cpm), along with 1 mg of poly(dI-dC) for the
nuclear extract or 100 ng of poly(dI-dC) for the purified with LTR-CAT/tat led to facilitation of DXM-mediated inhi-
bition (P  0.05). This inhibitory effect was also abro-GR, were added in a binding buffer with a final concentra-
tion of 20 mM Tris/HCl, pH 7.9, 1 mM EDTA, 0.05% NP40, gated by RU486 (Table 2).
The third major lineage of immune cell was repre-10% glycerol, 50 mM KCl, and 1 mM DTT. Protein–DNA
complexes were resolved by electrophoresis on a 5% sented by U937, a CD4/ promonocytic line. As in the
previous experiments, upregulation of CAT expressionnon-denaturing polyacrylamide gel (40:1 acrylamide:bis)
run at 15 V/cm, in 0.51 TBE. Gels were exposed over- by tat/LTR-CAT co-transfection was observed (Table 2).
However, in marked contrast to the T and B lymphocytenight for autoradiography. In some instances, a rabbit
antiserum to purified LBP-1 and pre-immune rabbit anti- lines, DXM had no effect on CAT activity in these cells
at any level of enzymatic activity. This was not a resultsera, obtained from Dr. Robert G. Roeder of Rockefeller
University, New York and previously characterized, (Yoon of the low basal expression of GR receptor in U937, ap-
proximately 1800/cell (Soudeyns et al., 1989), as introduc-et al., 1994) was used.
Conditions were identical in the competition assays, tion of exogenous GR did not reverse the inability of DXM
to alter CAT activity (Table 2). This was noted in multipleexcept that competitor DNA was included in the reaction
mixture before addition of nuclear extracts. experiments over a wide range of hormone concentra-
tions (1005 to 1009 M) (data not shown). It was replicated
in another cell line, THP-1, further along in the monocyteRESULTS
differentiation pathway. Again, minimal to no inhibition
Glucocorticoid modulation of HIV LTR-mediated gene
by DXM, unaffected by introduction of GR, was noted
expression
(data not shown).
To prove that the inhibitory effect of DXM in lym-The ability of DXM to modulate HIV-1 LTR-directed
transcription of a reporter gene, CAT, and its relationship phoblastoid cells was LTR specific, and not secondary
to global glucocorticoid-mediated effects such as cytoly-to GR density and cell lineage, was first investigated in
two T cell types. Jurkat represents a CD4/ T cell arrested sis or induction of apoptosis, we used two other viral
promoters along with the HIV-LTR construct pU3R3. Inearly in the course of T lymphocyte ontogeny, while SK23
is a CD4/ T cell hybridoma prepared using a develop- agreement with published studies (Cato et al., 1988),
DXM upregulated activity of a MMTV promoter linked tomentally later CD4/ T cell line, KE37. Data are shown
for SK23, albeit results were analogous in Jurkat. DXM CAT, represented by the vector pMAMNeoCAT (Clon-
tech, CA), and had no effect on SV40 promoter activitywas added at varying times after culture initiation, and
levels of CAT expression assessed in all samples after in plasmid pSV2CAT transfections (Table 3). However,
significant inhibition was observed with the HIV-LTR,45 hr of culture. In this experiment, DXM led to approxi-
mately 40% suppression of LTR-mediated CAT expres- here performed in the absence of tat, to obtain equivalent
baseline levels of CAT expression for all experimentssion when present in culture for at least 24 hr (Table 1).
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TABLE 2
Effect of DXM on tat-Activated, HIV-1–LTR-driven CAT Expression in T, B, and Monocyte Cell Lines
Assessment of CAT activity
T (SK23) % acetylation (% inhibition)
Experimental condition % acetylation mean (range) % inhibition B (Raji) Monocyte (U937)
1. pU3R3 (LTR) 2 (0.5–3.0) — 0.5 1.0
2. pU3R3 / pCV-1 (Tat) 61 (45–97) — 47 41
3. pU3R3 / Tat / DXM 21 (1–46) 45–98 28 (40%) 37 (9%)
4. pU3R3 / Tat / pRSVGR (GR) 84 (58–96) — 35 39
5. pU3R3 / Tat / GR / DXM 12 (1–20) 65–98 11 (68%) 38 (2%)
6. pU3R3 / Tat / GR / DXM / RU486 69 (55–88) 5–19 28 39
Note. Transfections and CAT assays were conducted as described in Materials and Methods. All experiments were performed five times; means
are recorded for all samples, with the ranges indicated for the T cells. Plasmids: pU3R3, wild-type HIV-1 LTR; pCV-1, tat; pRSVGR, glucocorticoid
receptor (GR).
(Table 3). In addition, treatment of all cell lines with 1006 oligo, but not by nonspecific oligomers (Fig. 2a). Next,
we sought to determine whether GRE-II and GRE-III wereM DXM for 48 hr had no effect on cell viability, as as-
sessed by trypan blue dye exclusion, nor did it induce able to independently bind GR. We used 27 nucleotide
oligomers from the HIV-1 LTR, 018 to /9 for GRE-II andDNA fragmentation (data not shown).
/6 to /32 for GRE-III, in gel shift assays. Both oligomers
GRE domains in the HIV-1 LTR bound specifically to the DNA binding domain of GR, with
binding inhibitable by cold consensus GRE oligo, but not
In addition to the GR binding sequence GRE-I, we iden-
by nonspecific oligos (Figs. 2b and 2c).
tified two additional GRE half-sites in the HIV-1 LTR (Fig.
1). TGTACT is at06 to01, just upstream of the transcrip-
Functional analysis of potential GRE domains in thetional start site, and is referred to as GRE-II, while AGA-
HIV-1 LTRCCA, at /15 to /20 (GRE-III), is 14 bp downstream. First,
we sought to determine whether GRE-II and -III are capa- Plasmid p142 CAT represents a gross deletion of the
ble of binding GR, as previously demonstrated for GRE- entire NRE (sequences upstream of 0142), including
I (Ghosh, 1992). We used a fragment comprising both GRE-I. We first tested the effect of DXM on basal CAT
GRE half-sites, nucleotides018 to/79, in an electropho- expression directed by this mutant LTR in the presence
retic mobility shift assay. This fragment bound specifi- and absence of tat. DXM inhibited such expression by
cally to the purified DNA binding domain of GR, as the almost 50% at 1007 M, rising to 97% inhibition at 1006 M
interaction was competed out with the consensus GRE (Table 4), in the absence of tat. This suppression was
blocked by RU486 (Table 4). As expected, CAT activity
was augmented following tat/LTR-CAT co-transfection,
TABLE 3
and this enhanced activity was also blocked by DXM.
Comparison of Effects of DXM on the HIV-1 and Murine Mammary The inhibitory effect of DXM on HIV LTR-mediated CAT
Tumor Virus LTRs and on the SV40 Promoter in CD4/ T Cells expression was unaffected by GRE-I deletion (Table 5).
However, this gross deletion affects multiple regulatoryCAT activity
sequences. Discrete removal of the GRE-I, without per-
Plasmids DXM (1006 M) % acetylation % inhibition turbing the spatial configuration of adjacent regions, was
accomplished using a linker scanning mutant, substitut-
pU3R3 0 6.1 0 ing an NdeI–XhoI–Sal I polylinker for nucleotides 0273
pU3R3 / 2.2 63.9
to 0256. This mutant behaved identically to p142 CAT,MMTV-LTR-CAT 0 1.5 0
confirming that GRE-I is not involved in DXM mediatedMMTV-LTR-CAT / 6.8 0 (/353.3)
pSV2-CAT 0 5.8 0 inhibition of LTR activity (Table 5). This result is consis-
pSV2-CAT / 6.1 0 (/5.1) tent with the work of others showing, by mutational analy-
sis, that GRE-I does not have a functional role in HIV
Note. 5 mg of HIV-LTR construct pU3R3, MMTV-LTR pMAMNeoCAT,
transcription (Soudeyns et al., 1993).or SV40 pSV2CAT plasmid DNA was transfected in 107 SK23 cells. CAT
We had previously explored the effect of DXM on GRE-assays were performed on 10 mg of protein from cell extracts, prepared
after 45 hr of cell culture. I linked to a heterologous promoter, tk. In contrast to the
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FIG. 2. Electrophoretic mobility shift assays with purified DNA binding domain of glucocorticoid receptor. (a) Binding of HIV-1 LTR fragment 018
to /79 to GR. Lane 1, probe; lane 2, 100 ng purified GR; lanes 3, 4, and 5, 50-, 100-, and 200-fold cold consensus GRE oligo; lanes 6 and 7, 100-
and 200-fold cold nonspecific oligo. An arrow indicates the shifted band, while free oligo appears at the bottom of all lanes. The third uppermost
band, in lanes 4, 6, and 7, may represent shifted dimers. (b) Binding of GRE-II oligonucleotide sequence (018 to /9) to GR. Lane 1, probe; lane 2,
200 ng purified GR; lanes 3, 4, and 5, 50-, 100-, and 200-fold cold consensus GRE oligo; lane 6, 200-fold cold nonspecific oligo. (c) Binding of GRE-
III oligonucleotide sequence (/6 to /32) to GR. Lane 1, probe; lane 2, 200 ng purified GR; lane 3, 200-fold cold consensus GRE oligo; lane 4, 200-
fold cold nonspecific oligo.
present results, GRE-I functioned as a classic transcrip- (/15//20), in which AGACCA has been changed to TTT-
AAA. In agreement with other data (Jones et al., 1988),tional enhancer when removed from the context of the
intact HIV-1 LTR (Sikder et al., 1994). This result is fully mutations in this region reduced the magnitude of LTR-
mediated transactivation by tat from 20- to 25-fold to 4-consistent with its sequence homology to known GRE
consensus enhancers. to 6-fold. However, lower levels of CAT activity did not
interfere with our ability to discern a DXM effect. LevelsTo define the role of the GRE-II site, we created a
double mutant construct, pA87CAT, in which AGAACA of of CAT expression with the GRE-III mutant in the presence
of tat (Table 5) were identical to that obtained with theGRE-I was changed to ACTTCA, and TGTACT of GRE-II
to TACACT. This construct behaved identically to the wild-type LTR in the absence of tat (Table 3), and yet DXM
suppressed wild-type LTR-mediated gene expression inwild-type LTR in all experiments (Table 5). We also used
a clustered point mutant in the region of GRE-II (05//1), the presence and absence of tat, but had no effect on
the GRE-III mutant LTR with or without tat (Table 5). Thisin which TGTACTG was changed to TTGCGCA. Again,
no significant change in the magnitude of inhibition of indicates that the GRE-III site is likely to be responsible
for DXM mediated suppression of HIV-1 gene expression.the CAT expression was noted (Table 5). These data
indicate that GRE-II is also not involved in adrenal steroid
Specificity of DXM-mediated transcriptional inhibitionsuppression of HIV-LTR gene expression.
Finally, we used a clustered point mutant in GRE-III We next sought to determine whether GRE-III is capa-
ble of binding to cellular factors in the nuclear extracts
of our cell lines, and whether there was any cell typeTABLE 4
specificity to this binding. We used four sets of oligomers
Effect of DXM on Activity of GRE-I Mutant/HIV-LTR-CAT
for these experiments: the consensus GRE (Promega),in CD4/ T Cells
GRE-I (0274 to 0256), GRE-II (018 to /9), and GRE-III
CAT activity (/6 to /32), in an EMSA with nuclear extracts prepared
from T (SK23), B (Raji), and monocytic (U937) cell lines.
Plasmid DXM RU486 % acetylation % inhibition As shown in Fig. 3a, the GRE III-oligo forms three distinct
DNA protein complexes in T and B lymphocytes, labelledp142CAT — 0 85.8 —
r1, r2, and r3 (top-to-bottom). In contrast, this profilep142CAT 1007 M 0 53.5 37.6
p142CAT 1006 M 0 2.1 97.6 is different in monocytic cells, notable for the absence
p142CAT 1006 M 1006 M 76.8 10.5 of the uppermost (r1) complex. The consensus GRE
oligo gave a similar pattern for these three cell types
Note. 5 1 106 SK23 cells were transfected with p142CAT (NRE de-
(Fig. 3b), although the intensity of band r1 varied.leted HIV-1 LTR construct) plasmid DNA, and CAT assays were per-
Specificity for nuclear extract binding to the GRE con-formed on cellular extracts prepared after 45 hr of cell culture. 10 mg
of cellular protein extract were used per condition. sensus and the three GRE HIV elements was next de-
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TABLE 5
DXM-Mediated Inhibition of CAT Expression in T Cells Driven by HIV-LTR Constructs with GRE Mutations
Assessment of CAT activity
% acetylation
/tat
Plasmids LTR-GRE mutant 0tat 0DXM /DXM % inhibition (/tat)
1. pU3R3 Wild type 2.0 66 23 65.2
2. p142CAT GRE-I 4.0 77 36 53.2
3. p-273/-256NXS.CAT GRE-I 3.0 76 35 53.9
4. pA87CAT GRE-I & II 3.0 67 22 67.1
5. p-5//1CPM.CAT GRE-II 2.0 31 16 48.4
6. p/15//20 CPM.CAT GRE-III 1.5 6 5.6 6.7
Note. The percentage of CAT acetylation in the presence and absence of DXM (1006 M), with percentage of inhibition of wild-type and GRE
mutant HIV-1 LTR constructs, is shown for transient transfection assays in SK23 CD4/ T cells. All experiments involved cotransfection of LTR-CAT
/ tat plasmids, except as indicated, and were repeated at least five times. Cell cultures were maintained for 42–45 hr.
fined. Band r2, being present in all three cell types and (r3) was nonspecific, unchanged in the presence of any
oligo.inhibitable by cold consensus GRE oligo (Fig. 3c), is iden-
tified as the GR complex. Nonspecific banding patterns As the uppermost shifted complex (r1) is absent in
U937 cells (Fig. 3a), in which DXM does not have anwere observed with GRE-I and GRE-II, with binding com-
pletely inhibited with cold nonspecific oligos (data not inhibitory effect, we hypothesized that this complex for-
mation is involved in GR-mediated inhibition of HIV-LTRshown). However, binding of T (Fig. 3c) and B lymphocyte
(data not shown) nuclear extracts to GRE-III was specific, directed transcription in T and B cells. We searched for
known DNA binding proteins other than GR that mightwith bands r2 and r1 inhibitable by cold specific oligo
but not by nonspecific oligo (Fig. 3c). The third complex interact with this region of the LTR, and found that the
FIG. 3. Electrophoretic mobility shift assays of GRE-III and consensus GRE oligo with nuclear extracts prepared from T, B, and monocytic cells.
r1 indicates leader binding protein (LBP)-1; r2, glucocorticoid receptor; and r3, a non-specific band. (a) Binding of GRE-III oligo (/6 to /32) to
nuclear extracts of T, B and monocytic cells. Lane 1, probe; lane 2, Raji (B); lane 3, U937 (monocyte); and lane 4, SK23 (T). (b) Binding of consensus
GRE oligo to nuclear extracts. Lane 1, probe; 2, Raji; 3, U937; and 4, SK23. (c) Specificity of binding of GRE-III oligo to SK23 T cell extracts. Lane
1, probe / SK23 extract; lanes 2, 3, and 4, 25-, 50-, and 100-fold cold GRE-III oligo; lane 5, 100-fold cold nonspecific oligo. (d) LBP-1/GR interactions.
The effect of an antiserum to LBP-1 on GRE-III binding to SK23 extracts was assessed. Lane 1, probe / SK23 extract / 1 ml pre-immune rabbit
serum; lane 2, 1 ml antiserum to LBP-1 added to extract. (e) Binding of consensus AP-1 oligomer to nuclear extracts. Lane 1, probe; lane 2, Raji;
lane 3, SK23; lane 4, U937.
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GRE-III sequence overlaps with a high-affinity LBP-1 site The precise means by which glucocorticoids nega-
tively regulate HIV-1 LTR-mediated gene expression isat 017 to /27. Indeed, an anti-LBP-1 antibody inhibited
formation of the upper complex, whereas pre-immune uncertain. No clear consensus sequence for negative
regulation exists (Beato, 1991). However, several modelssera had no effect (Fig. 3d). These experiments were
repeated three times, with identical results. have been proposed for such repression at the transcrip-
tional level. One widely accepted strategy is that of com-As a control for the integrity of the U937 extracts, the
binding of an AP-1 oligomer to nuclear extracts from all petition among a hormone receptor and cellular tran-
scription factors. Receptor bound to specific sites coinci-three lineages was examined. All behaved identically in
their interactions with AP-1 (Fig. 3e). These data indicate dent with or overlapping those of positive factors may
interfere with the binding of these molecules, therebythat GRE-III binds specifically to both LBP-1 and GR in
T and B cells, while LBP-1 binding to this sequence is squelching transcriptional activation (Akerblom et al.,
1988; Drouin et al., 1989; Schule et al., 1990; Chatterjeenot seen in monocytes.
et al., 1991; Scheinman et al., 1995). Such ‘‘trans-repres-
sion’’ is often modulated by nuclear receptor monomers,DISCUSSION
in the absence of new protein synthesis, and need in-
volve only GRE half-sites (Herrlich et al., 1994).We examined the effects of a prototype glucocorticoid,
dexamethasone, on HIV–LTR directed gene expression In the HIV-1 LTR, the GRE-III half-site (/15 to /20)
overlaps with the high affinity LBP-1 element, (017 toand its relationship to GRE consensus sequences in the
LTR. Our data show that DXM inhibits LTR-CAT expres- /27) (Fig. 1). Mutation of nucleotides /15 to /20 of the
LTR markedly reduces LBP-1 binding and transcription,sion in T and B lymphocyte lines. This suppression was
augmented by exogenous glucocorticoid receptor. Speci- implying that LBP-1 may here act as a positive transcrip-
tion factor (Jones et al., 1988). Based on our data, weficity of the DXM-receptor interaction was confirmed by
abrogation of this inhibition by RU486. In contrast to the believe that GR, by also binding in this region, inhibits
the binding of LBP-1 in T and B lymphocytes and therebyinteraction between the T3 thyroid hormone receptor and
Tat, which appears to subserve the activation of HIV- negatively regulates transcription.
As GRE-III is also in the viral mRNA, and could thusLTR gene expression by T3 (Desai-Yajnik et al., 1995),
inhibition was obtained in the presence and absence mediate a post-transcriptional effect in response to DXM,
we performed in vitro transcription reactions utilizing theof tat.
Cell type restriction was shown by the inability of DXM HIV-1 LTR and HeLa nuclear extracts. Analysis of run-off
transcripts indicated that 1006 M DXM efficiently down-to alter HIV–LTR transcription in monocytic cells, in the
presence or absence of exogenous GR. This latter effect regulated HIV–LTR transcription (data not shown).
The finding of a difference in LBP-1 binding patternswas not related to some global resistance of such cells
to glucocorticoids, as DXM can downregulate Fc recep- between lymphocyte and monocyte extracts is consistent
with reports of differences in LBP-1 activity in other sys-tor and interleukin-1 gene expression in these lines
(Knudsen et al., 1982). Attention to such differences may tems. For example, LBP-1 appears to have no effect on
HIV-1 LTR activity in differentiated monocytes, but sup-be important in anti-viral strategies directed at tissue
compartments where one type of cell preferentially repli- presses LTR activity in undifferentiated cells of this lin-
eage (Moses et al., 1994). In addition, LBP-1 may not becates or transmits HIV. For example, the monocyte/Hof-
bauer cell appears to be the predominant source of infec- the only cellular transcription factor that can bind in this
area and interact with GR. Finally, GR interactions withtious HIV in placental tissues (Mattern et al., 1992).
We subsequently evaluated the role of GR and other HIV gene products may also need to be considered as,
for example, GR appears to bind to Vpr (Refaeli et al.,cellular factors in this negative regulation, utilizing one
previously identified element, GRE-I, and two potential 1995).
These studies have potential clinical implications.GR binding sites in the HIV-1 LTR which we have identi-
fied here. These latter two elements, at nucleotides 06 Complications of HIV disease are often treated with glu-
cocorticoids. These include immune thrombocytopenicto 01 (GRE-II) and /15 to /20 (GRE-III), are highly con-
served among HIV-1 isolates (Myers et al., 1991). They, purpura, thrombotic thrombocytopenic purpura, lymphoid
interstitial pneumonitis, severe Pneumocystis cariniilike GRE-I, bound specifically to the purified DNA binding
domain of GR, albeit only GRE-III appeared to do so pneumonia, mucocutaneous exanthema, neuropathies,
and nephropathies (Laurence et al., 1989). Recently, thespecifically with nuclear extracts. EMSA also showed
co-binding of GRE-III and a second cellular protein, the National Institutes of Health has approved a clinical trial
of glucocorticoids in AIDS patients with nephropathy, fol-transcriptional factor LBP-1, only in T and B cells. These
data parallel the LTR-GRE transfection experiments, by lowing not only the course of their renal disease but also
the potential effects of these steroids on viral load andwhich DXM was shown to have no suppressive effect in
monocytic cell lines. immune function (AIDS Clinical Trials Group (ACTG) pro-
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Drouin, J., Trifiro, M. A., Plante, R. K., Nemer, M., Eriksson, P., andtocol 258). Another study, involving the treatment of 44
Wrange, O. (1989). Glucocorticoid receptor binding to a specific DNAHIV-1/ asymptomatic individuals with CD4/ T cell counts
sequence is required for hormone-dependent repression of proopio-
of 200–500/mm3 with the glucocorticoid prednisone (0.5 melanocortin gene transcription. Mol. Cell. Biol. 9, 5305.
mg/kg body weight per day), showed an increase in Garcia, J. A., Harrich, D., Soultankis, E., Wu, F., Mitsuyasu, R., and
Gaynor, R. B. (1989). Human immunodeficiency virus type 1 LTR TATACD4/ T cell counts and a stabilization of viral load, follow-
and TAR region sequence required for transcriptional regulation.ing an initial decline in viral burden, which was main-
EMBO J. 8, 765.tained for greater than 1 year (Andrieu et al., 1995). This
Ghosh, D. (1992). Glucocorticoid receptor-binding site in the human
clinical observation is consistent with the effects of glu- immunodeficiency virus long terminal repeat. J. Virol. 66, 586.
cocorticoid on CD4/ T cell apoptosis and HIV replication Giguere, V., Hollenberg, S. M., Rosenfield, M. G., and Evans, R. M.
(1986). Functional domains of the human glucocorticoid receptor.in primary cells (Lu et al., 1995) and with our experiments.
Cell 46, 645.Thus, definition of the mechanism of GR-mediated inhibi-
Grunstein, M., and Hogness, D. (1975). Colony hybridization: A methodtion of HIV–LTR-mediated transcription may assist in the
for isolation of cloned DNAs that contain a specific gene. Proc. Natl.
design of improved therapeutic strategies utilizing adre- Acad. Sci. USA 72, 3961.
nal steroids in HIV disease. Herrlich, P., and Ponta, H. (1994). Mutual cross-modulation of steroid/
retinoic acid receptor and AP-1 transcription factor activities. Trends
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